The latest from CDMOs, CMOs, and suppliers featuring Piramal Pharma, Famar Group, Recipharm/ProductLife Group and Ecolab Life Sciences.  

Biologics Manufacturing 
* Ecolab Opens New Bioprocessing Lab 
Formulation Development/Drug Product Manufacturing 
* Famar To Acquire Sterile Mfg Site in Germany 
General 
* Piramal Pharma To Invest $90 M Across Two US Facility Expansions 
* Recipharm, PLG Partner To Expand To Expand Capabilities  

---

Biologics Manufacturing 

Ecolab Opens New Bioprocessing Lab 
Ecolab Life Sciences has opened a new US bioprocessing applications laboratory in King of Prussia, Pennsylvania.  

The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecules from small-scale to full commercial production. The lab is equipped with high-throughput process development tools and manufacturing-scale chromatography columns to support process development as well as early- to late-stage and commercialization, including characterizing alternative resins. 

Source: Ecolab Life Sciences 

---

Formulation Development/Drug Product Manufacturing 

Famar To Acquire Sterile Mfg Site in Germany 
Famar Group, an Athens, Greece-based CDMO of drug products, has agreed to acquire a sterile production site in Homburg (Saar), Germany, from MiP Pharma, a mid-sized bio/pharmaceutical company.

The Homburg facility has recently undergone investment and modernization. When the transaction closes, Famar will operate seven facilities across Europe. Following closing, approximately 100 employees will transfer to Famar. The site will be developed into a multi-customer CDMO platform under Famar ownership. 

Source: Famar Group 

---

General 

Piramal Pharma To Invest $90 M Across Two US Facility Expansions 
Piramal Pharma, a CDMO of active pharmaceutical ingredients and drug products, has announced a $90-million investment plan to expand two of the company’s US facilities. 

The first expansion is at the company’s facility in Lexington, Kentucky, which specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site’s expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—will provide commercial-scale manufacturing to support scale-up of injectable drug products. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and on line by late 2027. 

The second expansion is at the company’s site in Riverview, Michigan, which specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and high-potency APIs. The company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers, which are used in the development of antibody-drug conjugates and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025. 

Source: Piramal Pharma 

---

Recipharm, PLG Partner To Expand Capabilities 
Recipharm, a CDMO of drug substances and drug products, and ProductLife Group (PLG), a consulting company, have entered a strategic collaboration to expand the companies’ capabilities. The collaboration brings together Recipharm’s development and manufacturing capabilities across small molecules, traditional biologics, and advanced therapies medicinal products with PLG’s expertise in product development, regulatory affairs and market access. By combining forces, the two companies will provide support from early-stage development to approval and market access. 

Source: Recipharm